Macular Degeneration
Conditions
Keywords
EYLEA, Age-Related Macular Degeneration, QOL
Brief summary
The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.
Interventions
DRUGAflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Patients treated with EYLEA under practical manner for AMD.
Sponsors
Regeneron Pharmaceuticals
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who have been determined to start EYLEA treatment * Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858) * Patients who have agreed with the patient informed consent
Exclusion criteria
* Patients who have already received EYLEA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in mean NEI-VFQ-25 overall scores of patients after the first intravitreal(ITV) injection of EYLEA | From baseline to 6 and 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Changes in mean NEI-VFQ-25 subscale scores of patients after the first ITV injection of EYLEA | From baseline to 6 and 12 months |
| Changes in mean NEI-VFQ-25 overall scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc | From baseline to 6 and 12 months |
| Changes in mean NEI-VFQ-25 subscale scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc | From baseline to 6 and 12 months |
Countries
Japan
Outcome results
None listed